Published in Cell Stress Chaperones on August 08, 2012
STA-9090(Ganetespib) in Metastatic Ocular Melanoma | NCT01200238
Cytoplasmic accumulation of NCoR in malignant melanoma: consequences of altered gene repression and prognostic significance. Oncotarget (2015) 0.77
Proteasome inhibitors against amelanotic melanoma. Cell Biol Toxicol (2017) 0.76
Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma. Front Oncol (2016) 0.75
Heat shock protein-90 inhibitors enhance antigen expression on melanomas and increase T cell recognition of tumor cells. PLoS One (2014) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
HSP90 and the chaperoning of cancer. Nat Rev Cancer (2005) 11.98
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones (2005) 5.22
Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci (2006) 4.04
The Hsp90 chaperone machinery. J Biol Chem (2008) 3.79
Heat shock protein 90: the cancer chaperone. J Biosci (2007) 3.05
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A (2005) 2.93
Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One (2009) 2.47
Heme oxygenase-1 in tumors: is it a false friend? Antioxid Redox Signal (2007) 2.03
Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol (1997) 1.98
Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst (1993) 1.95
High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res (2007) 1.88
Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am J Pathol (2006) 1.44
Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol (2004) 1.39
Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol (2002) 1.34
Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest (2009) 1.19
Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution. Urology (1996) 1.17
HSP90 as a marker of progression in melanoma. Ann Oncol (2007) 1.11
Melan-A, a new melanocytic differentiation marker. Adv Anat Pathol (1999) 1.07
Heat shock protects WEHI-164 target cells from the cytolysis by tumor necrosis factors alpha and beta. Eur J Immunol (1989) 1.06
Expression of HSP 90, PTEN and Bcl-2 in conjunctival melanoma. Br J Ophthalmol (2010) 1.02
Heat shock protein 70 membrane expression and melanoma-associated marker phenotype in primary and metastatic melanoma. Melanoma Res (2003) 1.01
Heat shock protein expression in the eye and in uveal melanoma. Invest Ophthalmol Vis Sci (2003) 0.95
Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. Int Immunol (1998) 0.94
Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Arch (1995) 0.93
Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Eur J Surg Oncol (2001) 0.92
HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes. Anticancer Res (2006) 0.86
Heat shock protein expression in target cells infected with low levels of replication-competent virus contributes to the immunogenicity of adenoviral vectors. Hum Gene Ther (1999) 0.86
Heat shock proteins and the antitumor T cell response. Biotherapy (1998) 0.85
Immune expression and inhibition of heat shock protein 90 in uveal melanoma. Clin Cancer Res (2008) 0.84
Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. Blood (2007) 0.83
Restoration of MHC class I surface expression and endogenous antigen presentation by a molecular chaperone. Scand J Immunol (1997) 0.83
Expression of the heat shock cognate protein HSP73 correlates with tumour thickness of primary melanomas and is enhanced in melanoma metastases. Int J Oncol (2004) 0.83
T cell epitope definition by differential mass spectrometry: identification of a novel, immunogenic HLA-B8 ligand directly from renal cancer tissue. Proteomics (2006) 0.79
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Epigenetic and immune function profiles associated with posttraumatic stress disorder. Proc Natl Acad Sci U S A (2010) 2.85
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Cytomegalovirus and human immunosenescence. Rev Med Virol (2009) 2.31
An immune risk phenotype, cognitive impairment, and survival in very late life: impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci (2005) 2.15
Age-associated accumulation of CMV-specific CD8+ T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). Exp Gerontol (2003) 2.11
Aging of the immune system as a prognostic factor for human longevity. Physiology (Bethesda) (2008) 2.09
Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One (2011) 2.08
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol (2012) 1.97
Aging and innate immunity. Immunity (2006) 1.95
Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. J Clin Immunol (2003) 1.94
Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci (2007) 1.87
The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech Ageing Dev (2006) 1.85
Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res (2009) 1.75
Is human aging still mysterious enough to be left only to scientists? Bioessays (2002) 1.59
Immunosenescence and vaccination in nursing home residents. Clin Infect Dis (2009) 1.57
Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing (2008) 1.57
Dysfunctional CMV-specific CD8(+) T cells accumulate in the elderly. Exp Gerontol (2004) 1.55
The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine (2012) 1.54
Human cytomegalovirus infection and T cell immunosenescence: a mini review. Mech Ageing Dev (2006) 1.53
No Immune Risk Profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study. Exp Gerontol (2007) 1.51
Biomarkers of human immunosenescence: impact of Cytomegalovirus infection. Curr Opin Immunol (2009) 1.51
Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother (2009) 1.44
Hallmark features of immunosenescence are absent in familial longevity. J Immunol (2010) 1.43
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin Cancer Res (2013) 1.43
Multi-parametric phospho-flow cytometry: a crucial tool for T lymphocyte signaling studies. Cytometry A (2013) 1.41
Role of CMV in immune senescence. Virus Res (2010) 1.35
The genetics of human longevity. Ann N Y Acad Sci (2006) 1.30
Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. J Gen Virol (2011) 1.29
The impact of CMV infection on survival in older humans. Curr Opin Immunol (2012) 1.28
Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer (2009) 1.24
Dysregulation of T-cell function in the elderly : scientific basis and clinical implications. Drugs Aging (2005) 1.23
Immunosenescence and Cytomegalovirus: where do we stand after a decade? Immun Ageing (2010) 1.22
Role of persistent CMV infection in configuring T cell immunity in the elderly. Immun Ageing (2007) 1.21
Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. Biogerontology (2006) 1.20
Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J Alzheimers Dis (2009) 1.20
Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal (2013) 1.19
Report from the second cytomegalovirus and immunosenescence workshop. Immun Ageing (2011) 1.19
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med (2013) 1.19
Mechanisms of immunosenescence. Immun Ageing (2009) 1.19
Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res (2009) 1.19
CMV and Immunosenescence: from basics to clinics. Immun Ageing (2012) 1.17
Gene expression analysis of mTOR pathway: association with human longevity. Aging Cell (2012) 1.17
Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer (2013) 1.17
An age-related increase in the number of CD8+ T cells carrying receptors for an immunodominant Epstein-Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev (2003) 1.17
Immunity, ageing and cancer. Immun Ageing (2008) 1.13
Aging, immunity, and cancer. Discov Med (2011) 1.11
Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine (2012) 1.10
Oxidative stress modulation and T cell activation. Exp Gerontol (2007) 1.10
Potential role of immunosenescence in cancer development. Ann N Y Acad Sci (2010) 1.10
High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer (2010) 1.07
Impact of age on T cell signaling: a general defect or specific alterations? Ageing Res Rev (2010) 1.07
Lower proportion of naïve peripheral CD8+ T cells and an unopposed pro-inflammatory response to human Cytomegalovirus proteins in vitro are associated with longer survival in very elderly people. Age (Dordr) (2012) 1.06
Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing - a biochemical paradigm for the ageing immune system. Arthritis Res Ther (2003) 1.05
Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res (2011) 1.04
OMIP-020: phenotypic characterization of human γδ T-cells by multicolor flow cytometry. Cytometry A (2014) 1.01
Immunosenescence and cancer. Crit Rev Oncol Hematol (2010) 1.00
Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma. Cancer Immunol Immunother (2010) 1.00
Immune receptor signaling, aging and autoimmunity. Adv Exp Med Biol (2008) 1.00
Impact of CMV and EBV seropositivity on CD8 T lymphocytes in an old population from West-Sicily. Exp Gerontol (2007) 0.99
Incisional biopsy and melanoma prognosis: Facts and controversies. Clin Dermatol (2010) 0.99
High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. Eur J Immunol (2005) 0.98
From bench to bedside and back: the SENIEUR Protocol and the efficacy of influenza vaccination in the elderly. Biogerontology (2008) 0.98
Immunosupportive therapies in aging. Clin Interv Aging (2007) 0.97
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res (2011) 0.96
Immune profiling of Alzheimer patients. J Neuroimmunol (2011) 0.94
Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma. PLoS One (2011) 0.94
NKp80 defines and stimulates a reactive subset of CD8 T cells. Blood (2008) 0.93
Rudimentary signs of immunosenescence in Cytomegalovirus-seropositive healthy young adults. Age (Dordr) (2013) 0.93
Gene expression changes in long-term culture of T-cell clones: genomic effects of chronic antigenic stress in aging and immunosenescence. Aging Cell (2007) 0.92
Age and immunity. Immun Ageing (2006) 0.91
Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands. Cancer Immunol Immunother (2006) 0.91
The European searchable tumour line database. Cancer Immunol Immunother (2009) 0.91
Age related microsatellite instability in T cells from healthy individuals. Exp Gerontol (2004) 0.91
Compromised interferon gamma (IFN-gamma) production in the elderly to both acute and latent viral antigen stimulation: contribution to the immune risk phenotype? Eur Cytokine Netw (2003) 0.90
Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother (2009) 0.90
Induction of HIF-1alpha and the glycolytic pathway alters apoptotic and differentiation profiles of activated human T cells. J Leukoc Biol (2009) 0.89
Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res (2014) 0.89
Cytomegalovirus seropositivity is associated with glucose regulation in the oldest old. Results from the Leiden 85-plus Study. Immun Ageing (2012) 0.89
HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones. Cancer Immunol Immunother (2001) 0.89
HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. Cancer Immunol Immunother (2007) 0.89
Prothymosin alpha: a ubiquitous polypeptide with potential use in cancer diagnosis and therapy. Cancer Immunol Immunother (2012) 0.88
Aging affects the proportions of T and B cells in a group of elderly men in a developing country--a pilot study from Pakistan. Age (Dordr) (2012) 0.88
Relationships between cancer and aging: a multilevel approach. Biogerontology (2009) 0.88